Text Size

Efficacy of Embryo Transfer Procedure Guided by Transvaginal Ultrasound Versus Abdominal Ultrasound in Oocytes Recipients

This study has been completed.
Sponsor:
Information provided by:
Fundació Privada Eugin
ClinicalTrials.gov Identifier:
NCT01137461
First received: June 3, 2010
Last updated: April 13, 2011
Last verified: April 2011
History of Changes
  Purpose

The objective of this study is to evaluate the efficacy of embryo transfer procedure guided by transvaginal ultrasound versus abdominal ultrasound in recipients of oocytes as well as the advantages and disadvantages of the new technique.


Condition Intervention Phase
Infertility
 Procedure: ultrasound-guided embryo transfer
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy of Embryo Transfer Procedure Guided by Transvaginal Ultrasound Versus Abdominal Ultrasound in Recipients of Oocytes. A Single-centre, Randomized Clinical Trial.

Resource links provided by NLM:

MedlinePlus related topics: Infertility
U.S. FDA Resources

Further study details as provided by Fundació Privada Eugin:

Primary Outcome Measures:
  • Clinical pregnancy rate [ Time Frame: 40 days after embryo transfer ] [ Designated as safety issue: No ]
    Evidence of gestational sac by transvaginal ultrasound


Enrollment: 330
Study Start Date: June 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
abdominal ultrasound
traditional technique
 Procedure: ultrasound-guided embryo transfer
Embryo transfer in oocyte recipients
transvaginal ultrasound
new technique
 Procedure: ultrasound-guided embryo transfer
Embryo transfer in oocyte recipients

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Oocyte recipients.
  • Uterus without previously detected anomalies.
  • Patients able to understand the study requirements who want to participate during all its duration and that have signed the informed consent.

Exclusion Criteria:

  • Turner syndrome, Black race (significantly lower implantational rates)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01137461

Locations
Spain
Clinica EUGIN
Barcelona, Spain, 08029
Sponsors and Collaborators
Fundació Privada Eugin
Investigators
Principal Investigator: Daniel Bodri Clinica EUGIN
  More Information

Additional Information:
Clínica EUGIN  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Dr. Daniel Bodri / Principal investigator, Clinica EUGIN
ClinicalTrials.gov Identifier: NCT01137461     History of Changes
Other Study ID Numbers: TATV
Study First Received: June 3, 2010
Last Updated: April 13, 2011
Health Authority: Spain: Comité Ético de Investigación Clínica

Keywords provided by Fundació Privada Eugin:
Female infertility with indication of oocyte reception

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female

ClinicalTrials.gov processed this record on June 18, 2013